Elsie,
Selective perception on your part. Deliberate and
Elsie,
Selective perception on your part. Deliberate and obvious intent to mislead.
You: "Gee. What's it been, about a year since the patents went up for sale and this is as close as we get for a sale."
The NanoLogix update:
"Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries."
NanoLogix did not have to tell us anything, but they did. They explained about patent issuance and registration and mentioned companies in three countries have shown interest.
They also mentioned China and the complications there with intellectual property (that would mean patents, in case you didn't know)
As for time elapsed for the sales effort, my understanding of when the patent could be sold is that it was dependent upon both registration (September 7) and individual registered countries publishing some announcement of the fact. So, your "about a year" is, in reality, at a maximum of about three months.
As I said, you have a severe case of deliberative selective perception and should seek help for it.
Scott
13
Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...
Continue Reading
Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...
Continue Reading
AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...
Continue Reading
Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...
Continue Reading
NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...
Continue Reading
A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...
Continue Reading
Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...
Continue Reading
Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...
Continue Reading
Gentex's Financial Outlook Takes a Hit Well, here we are again, catching another corporate hiccup. Gentex Corporation, or as ticker hounds know it, NASDAQ:GNTX, just pulled the rug out from its investors by chopping the top off its 2026 revenue guidance. Dropping to a floor it once considered a ceiling, $2.65 billion is now the most optimistic number they're pitching. No...
Continue Reading
Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....
Continue Reading
Top 5 Most Recently Viewed Articles
What a Turnaround! Numbers don’t lie, right? Well, take a look at MiMedx Group (NASDAQ:MDXG) and you see a company that’s done some real transformation. Their Q4 report came out on February 25, 2026, and it’s hard not to be impressed. They smashed the earnings estimate—by a whopping 40%. That’s no small feat in this market, especially when you look at the EPS...
Continue Reading
Intuitive Machines Schedules Conference Call for Financial Results Intuitive Machines, Inc. (Nasdaq: LUNR) has made an important announcement regarding its upcoming financial results. The company is set to release its fourth quarter and full-year financial outcomes, providing an in-depth look at its performance for 2024. This announcement will be made on a specific date...
Continue Reading
Understanding OSB Group PLC's Block Listing Return In the ever-evolving landscape of financial markets, regular disclosures play a pivotal role in maintaining transparency. Here, we delve into the latest block listing return from OSB Group PLC, outlining crucial details in a clear and concise manner. Key Details of the Block Listing Return It's essential for stakeholders...
Continue Reading
Gemini Launches Tokenized U.S. Equities In an exciting development for European investors, Gemini has expanded its offerings by facilitating the trading of tokenized U.S. equities. This marks a significant shift in providing easier access to international investment opportunities. Initially launched for its user base in Europe, Gemini aims to create a seamless experience...
Continue Reading
Vivian Health's New Era with CEO Bill Kong Vivian Health, a prominent player in the healthcare jobs marketplace, is transitioning into a new chapter under the leadership of Bill Kong, who has been appointed as the CEO. This strategic move follows the remarkable success achieved by Parth Bhakta, co-founder and outgoing CEO, who now assumes the role of Executive Chairman....
Continue Reading